natgillin/translations-raw huggingface dataset:
Enviage is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Zdravilo Enviage je na voljo v pakiranjih, ki vsebujejo po 7, 14, 28, 30, 50, 56, 84, 90, 98 ali
Enviage may be used alone or in combination with other antihypertensive agents (see sections 4.4 and 5.1).
Enviage se lahko jemlje samostojno ali v kombinaciji z drugimi učinkovinami za zniževanje krvnega tlaka (glejte poglavji 4.4 in 5.1).
Environmental Risk Assessment (ERA)
Ocena okoljskega tveganja (ERA – Environmental Risk Assessment)
Environmental Risk Assessment (ERA)
Ocena tveganja za okolje (ERA – Environmental Risk Assessment)
Environmental Risk Assessment (ERA)
Ocena tveganja za okolje (ERA)
Environmental Risk Assessment (ERA)
Ocena tveganja za okolje:
Enyglid is a ‘generic medicine’.
Zdravilo Enyglid je „generično zdravilo“.
Enyglid should not be taken if you have a severe liver disease (see Do not take Enyglid). if you have kidney problems.
Bolniki s hudo boleznijo jeter pa zdravila Enyglid ne smejo jemati (glejte odstavek Ne jemljite zdravila Enyglid). če imate težave z ledvicami.
enzalutamide
enzalutamidom
Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.
Enzalutamid kompetitivno zavre vezavo androgenov na androgenske receptorje, zavre jedrno translokacijo aktiviranih receptorjev in zavre povezavo aktiviranih androgenskih receptorjev z DNA tudi v okoliščinah čezmerne ekspresije androgenskih receptorjev in v celicah raka prostate, odpornih proti androgenom.
Enzalutamide did not induce mutations in the microbial mutagenesis (Ames) assay and was not clastogenic in either the in vitro cytogenetic assay with mouse lymphoma cells or the in vivo mouse micronucleus assay.
Enzalutamid ni povzročil mutacij v preskusu mikrobne mutageneze (Ames) ter ni bil klastogen ne v citogenetskem preskusu z mišjimi limfomskimi celicami in vitro ne v mišjem mikrojedrnem preskusu in vivo.
Enzalutamide does this by blocking the receptors to which these hormones attach and preventing them from responding.
Enzalutamid zavira receptorje, na katere se ti hormoni vežejo, kar preprečuje njihov odziv.
Enzalutamide is contraindicated in women who are or may become pregnant (see sections 4.3 and 5.3).
Enzalutamid je kontraindiciran pri nosečih ženskah in ženskah, ki bi lahko zanosile (glejte poglavji 4.3 in 5.3).
Enzalutamide is extensively metabolized.
Enzalutamid se izdatno presnovi.
Enzalutamide is metabolized by CYP2C8 and to a lesser extent by CYP3A4/5 (see section 4.5), both of which play a role in the formation of the active metabolite.
Enzalutamid se presnovi s CYP2C8 in v manjši meri s CYP3A4/5 (glejte poglavje 4.5); oba igrata vlogo pri nastanku aktivnega presnovka.
Enzalutamide is not a substrate of the efflux transporters P-gp or BCRP.
Enzalutamid ni substrat efluksnih prenašalcev P-gp ali BCRP.
Enzalutamide may have a moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizure have been reported (see section 4.8).
Enzalutamid ima lahko blag vpliv na sposobnost vožnje in upravljanja s stroji; opisani so bili namreč psihiatrični in nevrološki dogodki, vljučno s konvulzijami (glejte poglavje 4.8).
Enzalutamide significantly decreased the risk of the first skeletal-related event by 28% [HR = 0.718 (95% CI: 0.610, 0.844) p-value < 0.0001].
Enzalutamid je značilno zmanjšal tveganje pojava prvega z okostjem povezanega dogodka za 28 % [RT = 0,718 (95-odstotni IZ: 0,610; 0,844) vrednost p < 0,0001].
Enzepi 10,000
Enzepi 10.000
Enzepi 10,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 10.000 enot gastrorezistentne trde kapsule uprašeni pankreas
Enzepi 25,000
Enzepi 25.000
Enzepi 25,000 units gastro-resistant hard capsules
Enzepi 10.000 enot gastrorezistentne trde kapsule
Enzepi 25,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 25.000 enot gastrorezistentne trde kapsule uprašeni pankreas
Enzepi 25,000 units: hypromellose, carrageenan (E407), potassium chloride, titanium dioxide E171, carnauba wax, water, yellow iron oxide (E172), indigotine E132.
Enzepi 25.000 enot: hipromeloza, karagenan (E407), kalijev klorid, titanov dioksid (E171), karnauba vosek, voda, rumeni železov oksid (E172), indigotin (E132);
Enzepi 40,000
Enzepi 40.000
Enzepi 40,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 40.000 enot gastrorezistentne trde kapsule uprašeni pankreas
Enzepi 40,000 units gastro-resitant hard capsules
Enzepi 40.000 enot gastrorezistentne trde kapsule
Enzepi 5,000
Enzepi 5.000
Enzepi 5,000 units gastro-resistant hard capsules Enzepi 10,000 units gastro-resistant hard capsules Enzepi 25,000 units gastro-resistant hard capsules Enzepi 40,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 5.000 enot gastrorezistentne trde kapsule Enzepi 10.000 enot gastrorezistentne trde kapsule Enzepi 25.000 enot gastrorezistentne trde kapsule Enzepi 40.000 enot gastrorezistentne trde kapsule uprašeni pankreas
Enzepi 5,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 5.000 enot gastrorezistentne trde kapsule uprašeni pankreas
Enzepi does not affect your ability to drive or use tools or machines.
Zdravilo Enzepi nima vpliva na sposobnost vožnje in upravljanja orodja ali strojev.
Enzepi is for use by adults, adolescents, children and infants with ‘exocrine pancreatic insufficiency’, a condition that makes the body less able to break down and digest food.
Zdravilo Enzepi je namenjeno uporabi pri odraslih, mladostnikih, otrocih in dojenčkih s »pomanjkljivim eksokrinim delovanjem trebušne slinavke«, boleznijo, ki poslabša razgradnjo in prebavo hrane v telesu.
Enzepi pancreas powder
Enzepi uprašeni pankreas
Enzyme inducers (such as St. John’s wort [Hypericum perforatum], rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz) may give rise to decreased exposure of canagliflozin.
Induktorji encimov (kot so šentjanževka [Hypericum perforatum], rifampicin, barbiturati, fenitoin, karbamazepin, ritonavir in efavirenz) lahko povzročijo zmanjšano izpostavljenost kanagliflozinu.
Enzyme inducing medicinal products such as rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s wort (Hypericum perforatum) are likely to lead to reduced piperaquine plasma concentrations.
Verjetno je, da bodo zdravila, ki inducirajo encime, kot so rifampicin, karbamazepin, fenitoin, fenobarbital, šentjanževka (Hypericum perforatum), zmanjšala koncentracije piperakina v plazmi.
Enzyme induction wears off slowly and effects on the plasma concentrations of ulipristal acetate may occur even if a woman has stopped taking an enzyme inducer within the last 2-3 weeks.
Indukcija encimov pojema postopoma, učinki na plazemske koncentracije ulipristalacetata pa se lahko pojavijo, tudi če je ženska prenehala jemati induktor encimov v preteklih 2–3 tednih.
Enzyme induction: Exposure to zonisamide is lower in epileptic patients receiving CYP3A4-inducing agents such as phenytoin, carbamazepine, and phenobarbitone.
encimska indukcija: izpostavljenost zonisamidu pri epileptičnih bolnikih, ki so zdravljeni z zdravili, ki inducirajo CYP3A4, kot na primer fenitoin, karbamazepin in fenobarbiton je nižja.
enzyme inhibition)
(zaviranje prenašalca OATP1B1/3)
Enzyme-inducing drugs such as rifampicin, rifabutin, carbamazepine, isoniazid, nevirapine, mitotane and phenytoin may significantly reduce the bioavailability of Ketoconazole HRA.
Zdravila, ki inducirajo encime, kot so rifampicin, rifabutin, karbamazepin, isoniazid, nevirapin, mitotan in fenitoin, lahko pomembno zmanjšajo biološko uporabnost zdravila Ketokonazol HRA.
Enzymes that may be induced include CYP3A in the liver and gut, CYP2B6, CYP2C9, CYP2C19, and uridine 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enzymes).
Možni inducirani encimi lahko vključujejo CYP3A v jetrih in črevesju, CYP2B6, CYP2C9, CYP2C19 in uridin 5'-difosfat-glukuronil-transferazo (UGT – glukuronidni konjugacijski encimi).
enzymes, a similar
karbamazepin/dolutegravir
EOF: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m2 given as a 2 hour infusion on day 1 every three weeks), and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
EOF: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), oksaliplatin (130 mg/m2 v 2-urni infuziji 1. dan vsake tri tedne) in 5-FU (200 mg/m2 na dan v kontinuirani infuziji skozi centralni venski kateter);
eosinophil count increased
povečano število eozinofilcev
Eosinophil count increased
zvišana koncentracija eozinofilcev
Eosinophilia
eozinofilija
Eosinophilia
eozinofilijo in
Eosinophilia (in association with hypersensitivity skin reactions)
eozinofilija (v povezavi s preobčutljivostnimi kožnimi reakcijami)
Eosinophilia (increased number of a type of white blood cells in the blood)
eozinofilija (zvečano število ene od vrst belih krvničk v krvi),
Eosinophilia and
eozinofilijo in
Eosinophilia Leukopenia10 Neutropenia10
Eozinofilija Levkopenija10 Nevtropenija10
Eosinophilia thrombocytopenia
eozinofilija, trombocitopenija
Eosinophilia, lymphopenia
eozinofilija, limfopenija
Eosinophilia, thrombocytopenia
Redki: eozinofilija, trombocitopenija
Eosinophilia, thrombocytopenia,
Redki: eozinofilija, trombocitopenija
Eosinophilic asthma is a type of asthma where patients have too many eosinophils in the blood or lungs.
Eozinofilna astma je vrsta astme, pri kateri imajo bolniki v krvi ali pljučih preveč eozinofilncev.
Eosinophilic pneumonia1**, cough
eozinofilna pljučnica1**, kašelj
Eosinophils are thought to be associated with immune system responses to some parasitic infections.
Eozinofilci so domnevno povezani z odzivom imunskega sistema na nekatere infestacije s paraziti.
Eosinophils may be involved in the immunological response to some helminth infections.
Eozinofilci so lahko vpleteni v imunski odziv na nekatere infestacije s helminti.
EOT % (n/N)
KZ % (n/N)
EOT %, (n/N)
KZ % (n/N)
EOT %, (n/N)
KZ %, (n/N)
EOX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m2 given as a 2 hour infusion on day 1 every three weeks), and capecitabine (625 mg/m2 twice daily continuously).
EOX: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), oksaliplatin (130 mg/m2 v 2-urni infuziji 1. dan vsake tri tedne) in kapecitabin (625 mg/m2 dvakrat na dan neprekinjeno).
eparate syringe. separate needles.
brizga ločeni igli
eparation of one of the layers within the eyeball after surgery to reduce the pressure in the eye known risk factors for macular oedema (swelling of the retina within the eye leading to worsening vision), for example, cataract surgery
ločevanje ene plasti znotraj zrkla po kirurškem posegu za zmanjšanje tlaka v očesu; znane dejavnike tveganja za nastanek makularnega edema (otekanja mrežnice znotraj očesa, ki pripelje do poslabšanja vida), na primer kirurško zdravljenje katarakte.
eparation of one of the layers within the eyeball after surgery to reduce the pressure in the eye known risk factors for macular oedema (swelling of the retina within the eye leading to worsening vision), for example, cataract surgery
ločevanje ene plasti znotraj zrkla po kirurškem posegu za zmanjšanje tlaka v očesu; znane dejavnike tveganja za nastanek makularnega edema (otekanja mrežnice znotraj očesa,ki pripelje do poslabšanja vida), na primer kirurško zdravljenje katarakte.
Epclusa + ribavirin for 12 weeks
Zdravilo Epclusa + ribavirin 12 tednov
Epclusa 12 weeks
Zdravilo Epclusa 12 tednov
Epclusa 12 weeks (134)
Zdravilo Epclusa 12 tednov (134)
Epclusa 12 weeks (277)
Zdravilo Epclusa 12 tednov (277)
Epclusa 12 weeks (624)
Zdravilo Epclusa 12 tednov (624)
Epclusa 12 weeks (n = 134)
Zdravilo Epclusa 12 tednov (n = 134)
Epclusa 12 weeks (n = 277)
Zdravilo Epclusa 12 tednov (n = 277)
Epclusa 12 weeks (n = 624)
Zdravilo Epclusa 12 tednov (n = 624)
Epclusa 12 weeks (n = 90)
Zdravilo Epclusa 12 tednov (n = 90)
Epclusa 400 mg/100 mg film-coated tablets.
Epclusa 400 mg/100 mg filmsko obložene tablete.
Epclusa [Outer packaging only]
Epclusa [samo zunanja ovojnina]
Epclusa has been shown to increase tenofovir exposure, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).
Pokazalo se je, da zdravilo Epclusa poveča izpostavljenost tenofovirju, zlasti, če se uporablja skupaj z režimom proti HIV, ki vsebuje dizoproksiltenofovirijev fumarat in farmakokinetični ojačevalec (ritonavir ali kobicistat).
Epclusa has no or negligible influence on the ability to drive and use machines.
Zdravilo Epclusa nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Epclusa is a medicine that contains the active substances sofosbuvir and velpatasvir in a single tablet.
Zdravilo Epclusa je zdravilo, ki vsebuje zdravilni učinkovini sofosbuvir in velpatasvir v eni sami tableti.
Epclusa is contraindicated with rifabutin, a potent P-gp and CYP inducer (see section 4.3).
Zdravilo Epclusaje kontraindicirano v kombinaciji z rifabutinom, ki je močan zaviralec P-gp in citokromov CYP (glejte poglavje 4.3).
Epclusa is contraindicated with rifampicin, a potent P-gp and CYP inducer (see section 4.3).
Zdravilo Epclusa je kontraindicirano v kombinaciji z rifampicinom, ki je močan zaviralec P-gp in citokromov CYP (glejte poglavje 4.3).
Epclusa is contraindicated with St. John’s wort a potent P-gp and CYP inducer (see section 4.3).
Zdravilo Epclusaje kontraindicirano v kombinaciji s šentjanževko, ki je močan induktor P-gp in citokromov CYP (glejte poglavje 4.3).
Epclusa should not be administered concurrently with other medicinal products containing sofosbuvir.
Zdravila Epclusa se ne sme dati sočasno z drugimi zdravili, ki vsebujejo sofosbuvir.
Eperzan 30 mg powder and solvent for solution for injection.
Eperzan 30 mg prašek in vehikel za raztopino za injiciranje. albiglutid
Eperzan 30 mg powder and solvent for solution for injection. albiglutide
Eperzan 30 mg prašek in vehikel za raztopino za injiciranje. albiglutid
Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly at Week 6) was compared to liraglutide 1.8 mg daily (titrated up from 0.6 mg at Week 1 and 1.2 mg at Week 1 to Week 2) in patients inadequately controlled on monotherapy or combination oral antidiabetic therapy (metformin, thiazolidinedione, or sulphonylureas).
Zdravilo Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden teden) so primerjali z 1,8 mg liraglutida na dan (titriranega od 0,6 mg 1. teden in 1,2 mg 1. do 2. teden) pri bolnikih, neustrezno urejenih z monoterapijo ali kombinacijo peroralnih antidiabetikov (metformin, tiazolidindion ali sulfonilsečnine).
Eperzan 30 mg SC weekly was compared to placebo in patients inadequately controlled on pioglitazone 30 mg daily (with or without metformin 1,500 mg daily).
Zdravilo Eperzan 30 mg subkutano na teden so primerjali s placebom pri bolnikih, neustrezno urejenih z  30 mg pioglitazona na dan (z  1.500 mg metformina na dan ali brez njega).
Eperzan 30 mg Weekly + Pioglitazone
Eperzan 30 mg na teden + pioglitazon
Eperzan 50 mg powder and solvent for solution for injection.
Eperzan 50 mg prašek in vehikel za raztopino za injiciranje. albiglutid
Eperzan 50 mg powder and solvent for solution for injection. albiglutide
Eperzan 50 mg prašek in vehikel za raztopino za injiciranje. albiglutid
Eperzan can also be used as an ‘add-on’ to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of blood glucose.
Zdravilo Eperzan se lahko uporablja tudi kot „dodatek“ k drugim zdravilom za zdravljenje sladkorne bolezni, vključno z insulinom, kadar ta zdravila skupaj s telesno dejavnostjo in dieto ne zagotavljajo zadostne urejenosti glukoze v krvi.
Eperzan has no or negligible influence on the ability to drive or use machines.
Zdravilo Eperzan nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Eperzan is not recommended if you have these conditions.
Zdravilo Eperzan ni priporočljivo, če imate te bolezni.
Eperzan is used to help control your blood sugar, either:
Zdravilo Eperzan se uporablja kot pomoč za uravnavanje krvnega sladkorja, in sicer:
Ephedrine, due to a reduction in dexamethasone plasma levels by increased metabolic clearance.
efedrin, saj se zaradi povečanega presnovnega očistka zmanjšajo koncentracije deksametazona v plazmi;
Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.
Epidemiološki podatki iz obširne metaanalize kažejo rahlo zvečano tveganje pri ženskah, ki uporabljajo samo estrogensko HNZ, kar postane očitno po 5 letih uporabe in se po prenehanju sčasoma počasi zmanjšuje.
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
Tudi epidemiološke študije, , kažejo malo večje tveganje za rak mehurja pri bolnikih s sladkorno boleznijo zdravljenih s pioglitazonom, čeprav pri vseh študijah povečanje tveganja ni bilo statistično signifikantno
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone,although not all studies identified a statistically significant increased risk .
Tudi epidemiološke študije kažejo tudi malo večje tveganje za rak mehurja pri bolnikih s sladkorno boleznijo zdravljenih s pioglitazonom, čeprav pri vseh študijah povečanje tveganja ni bilo statistično signifikantno.
Epidemiological studies have not revealed malformative effects but have shown a risk for intra uterine growth retardation when beta-blockers are administered by the oral route.
Epidemiološke študije niso pokazale škodljivih učinkov na razvoj ploda, vendar pa je bilo ob oralni uporabi antagonistov adrenergičnih receptorjev beta ugotovljeno tveganje za upočasnitev intrauterine rasti.
Epidemiological studies have not revealed malformative effects but shown a risk for intra uterine growth retardation when beta-blockers are administered by the oral route.
Epidemiološke študije niso pokazale škodljivih učinkov na razvoj ploda, vendar pa je bilo ob oralni uporabi antagonistov adrenergičnih receptorjev beta ugotovljeno tveganje za upočasnitev intrauterine rasti.
Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population.
Epidemiološke študije so pokazale, da imajo bolniki s Parkinsonovo boleznijo večje tveganje (2- do približno 6-krat večje) za razvoj melanoma v primerjavi s splošno populacijo.
Epidemiological studies in women who use low dose (< 50 µg ethinylestradiol) combined hormonal contraceptives have found that out of 10,000 women between 6 and 12 will develop a VTE in one year.
Epidemiološke študije pri ženskah, ki jemljejo nizkoodmerne kombinirane peroralne kontraceptive (< 50 µg etinilestradiola), so pokazale, da se VTE v enem letu pojavi pri 6 do 12 od 10.000 žensk.
Epidemiological studies in women who use low dose (<50 µg ethinylestradiol) combined hormonal contraceptives have found that out of 10,000 women between 6 and 12 will develop a VTE in one year.
Epidemiološke študije pri ženskah, ki jemljejo nizkoodmerne kombinirane peroralne kontraceptive (< 50 µg etinilestradiola), so pokazale, da se VTE v enem letu pojavi pri 6 do 12 od 10.000 žensk.
Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving a drug from related pharmacological classes of antidepressants (SSRIs or TCAs).
Epidemiološke študije, opravljene večinoma pri bolnikih, starejših od 50 let, kažejo povečano tveganje za zlome kosti pri bolnikih, ki dobivajo antidepresive iz podobne farmakološke skupine (SSRI in TCA).
epidemiological studies\non-interventional or observational studies, or through an evaluation of individual case reports.
v epidemioloških študijah/neinterventnih ali opazovalnih študijah ali s presojo poročil posameznih primerov.
epidermal
epidermalna
Epididymal cyst Gynaecomastia
cista epididimusa ginekomastija
epididymitis, priapism, cervical dysplasia, breast mass, testicular pain, vulval ulceration, atrophic vulvovaginitis, infertility, scrotal oedema
vnetje nadmodka, priapizem, displazija materničnega vratu, zatrdlina v dojki, bolečina v modih, razjede vulve, atrofični vulvovaginitis, neplodnost, edem modnika
Epigastric discomfort Gastric dilatation Haematemesis
neugodje v epigastrični regiji, gastrektazija,
Epiglottitis*, otitis media, sepsis
epiglotitis*, vnetje srednjega ušesa, sepsa
Epilepsy
epilepsija,
Epilepsy
epilepsija;
epilepsy (e.g. primidone, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, topiramate, felbamate); tuberculosis (e.g. rifampicin);
epilepsije (npr. primidon, fenitoin, fenobarbital, karbamazepin, okskarbazepin, topiramat, felbamat);
epilepsy (or have been told that you are at risk of having fits)
epilepsijo (oziroma so vam povedali, da ste izpostavljeni tveganju za epileptične napade);
Epilepsy and/or compromised central nervous system (CNS) function (see section 4.4).
Epilepsija in/ali moteno delovanje osrednjega živčevja (CŽS) (glejte poglavje 4.4),
Epilepsy is a condition where the patients have repeated fits (seizures).
Epilepsija je stanje, kjer ima bolnik ponavljajoče se napade (krče).
Epilepsy is a condition where the patients have repeated fits (seizures).
Epilepsija je stanje, pri katerem imajo bolniki ponavljajoče se napade (krče).
epilepsy medicines (e.g. carbamazepine, divalproex, lamotrigine, phenytoin);
zdravila proti epilepsiji (npr. karbamazepin, divalproeks, lamotrigin, fenitoin);
Epilepsy or generalised anxiety disorder
Epilepsija ali generalizirana anksiozna motnja
Epilepsy or other seizure disorders not controlled by medication
epilepsijo ali druge oblike napadov, ki jih ni možno nadzorovati z zdravili,
epilepsy, lethargy, neuropathy peripheral
epilepsija, letargija, periferna nevropatija
epilepsy, where it is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
epilepsijo, pri čemer se uporablja kot dodatek k obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptični napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem; splošno anksiozno motnjo (dolgotrajno anksioznostjo ali živčnostjo zaradi vsakdanjih stvari).
epilepsy, where it is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
epilepsijo, pri čemer se uporablja kot dodatek k obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem; splošno anksiozno motnjo (dolgotrajno anksioznostjo ali živčnostjo v zvezi s vsakdanjimi stvarmi).
epilepsy, where it is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
epilepsijo, pri čemer se uporablja kot dodatek k obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem; splošno anksiozno motnjo (dolgotrajno anksioznostjo ali živčnostjo zaradi vsakdanjih stvari).